GlassScriptPhysician profile
Andre C L Liem
NPI 1942648787
$1,871.87
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
See the full distribution for Physical Medicine & Rehabilitation
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $559 · 2020: $789 · 2021: $464 · 2022: $36.77 · 2024: $23.09.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $23.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $23.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $473.33 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $450.01 | 2019-2021 | |
| Amgen INC. | $271.31 | 2019-2021 | |
| Glaxosmithkline, LLC. | $135.25 | 2019-2021 | |
| Exelixis INC. | $106.93 | 2020-2021 | |
| Eisai INC. | $104.87 | 2019-2021 | |
| Seagen INC. | $100.53 | 2020-2021 | |
| Celgene Corporation | $77.94 | 2021 | |
| Merck Sharp & Dohme LLC | $55.37 | 2019 | |
| Janssen Biotech, INC. | $43.07 | 2019-2020 | |
| Biotronik Nro, INC. | $23.09 | 2024 | Prospera |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.67 | 2019 | |
| Viiv Healthcare Company | $13.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andre Liem listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.